Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage + cerium oxide
- Development stage
- Preclinical
- Lead developer
- Nanjing Agricultural University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
Bacteriophage + cerium oxide (specifically studied as P510@CeO2) is an engineered biohybrid nanomedicine developed for the treatment of carbapenem-resistant *Klebsiella pneumoniae* (CRKP)-associated inflammatory bowel disease (IBD). It consists of a lytic bacteriophage (such as P510) targeting the ST11 KL64 strain of CRKP, covalently conjugated to catalytic cerium oxide ($CeO_2$) nanoparticles. The bacteriophage component provides precise targeting of CRKP by recognizing bacterial capsular polysaccharides and outer membrane proteins, leading to bacterial lysis. The cerium oxide nanoparticle component acts as a catalytic reactive oxygen species (ROS) scavenger and anti-inflammatory agent, alleviating oxidative stress and inflammation in the inflamed colon. This dual-action approach also downregulates capsule-encoding genes and inhibits efflux pumps to prevent the emergence of phage-resistant mutants, restores intestinal microbiota balance, and repairs the intestinal barrier.
- Other names
- P510@CeO2 nanoparticlesengineered phage (phage@CeO2)phage@CeO2 nanoparticles
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on bacteriophage + cerium oxide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage + cerium oxide.